China accepts CANbridge's NDA for CAN108 to treat cholestatic pruritus
The National Medical Products Administration (NMPA) of China has accepted the new drug application (NDA) submitted by CANbridge Pharmaceuticals for CAN108.
James Xue News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from James Xue. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In James Xue Today - Breaking & Trending Today
Taiwan approves CANbridge's CAN108 for treatment of cholestatic pruritus
The Taiwan Food and Drug Administration (TFDA) has granted marketing approval to CANbridge Pharmaceuticals’ CAN108 (LIVMARLI)
CANbridge Announces Interim Financial Results and Corporate Updates for the Six Months Ended June 30, 2023
/PRNewswire/ -- CANbridge Pharmaceuticals, Inc. ("CANbridge," stock code 1228.HK), a global biopharmaceutical company, with a foundation in China, committed to...
Source: prnewswire.com
CANbridge Reports Positive Preliminary Data in the Omoprubart (CAN106) Phase 1b Trial in Paroxysmal Nocturnal Hemoglobinuria (PNH) in China
Promising Efficacy and Safety With Four-Week Extended Dosing Data Shows Dose-Dependent Reduction of LDH and Increased Hemoglobin Levels That Demonstrate Clinically Meaningful Hemolysis Inhibition CANbridge Plans to
Source: benzinga.com
CANbridge Announces Marketing Approval of CAN108 (迈芮倍®/LIVMARLI®) in China for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome
LIVMARLI First and Only Treatment Approved in Mainland China for Cholestatic Pruritus in ALGS CANbridge to Hold Investor CallBEIJING & BURLINGTON, Mass. ...
Source: oilnow.gy